Metraipolis › archive › dc_ad6dfdf4bdfe

Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS — Europe PMC PMID:41774718

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41774718
DOI: 10.1371/journal.pone.0344190
License (as archived): solo-consultazione
Archived: 2026-10-08T01:59:17.668Z
SHA-256 of the archived text: b7ceca28f21b555ce3d93d45b5dadfe8346d4713d63d84ce93a56382371779da
Stable URL of this page: https://metraipolis.com/documento/dc_ad6dfdf4bdfe

How to cite

Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS — Europe PMC PMID:41774718 — Europe PMC (en), https://europepmc.org/article/MED/41774718 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ad6dfdf4bdfe (Metraipolis archive dc_ad6dfdf4bdfe, sha256 b7ceca28f21b555ce3d93d45b5dadfe8346d4713d63d84ce93a56382371779da)

BibTeX

@misc{dcad6dfdf4bdfe,
  title = {Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS — Europe PMC PMID:41774718},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41774718},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ad6dfdf4bdfe; sha256 b7ceca28f21b555ce3d93d45b5dadfe8346d4713d63d84ce93a56382371779da},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41774718. Agents can read the archived copy with the MCP tool read_document.